Infinium Pharmachem H1 FY27 Results: Net Profit ₹8.9 Cr, Up 58.9% YoY
Infinium Pharmachem Ltd reported revenue from operations of ₹129.7 Cr (+54.2% YoY) and net profit of ₹8.9 Cr (+58.9% YoY) for H1 FY27.
- Key figure
- Net profit ₹8.9 Cr · +58.9% YoY
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Infinium Pharmachem Ltd reported revenue from operations of ₹129.7 Cr (+54.2% YoY) and net profit of ₹8.9 Cr (+58.9% YoY) for H1 FY27.
Infinium Pharmachem Limited filed its quarterly SEBI Regulation 74(5) compliance certificate for the period ending September 30, 2026, confirming all shares are held in demat form.
Infinium Pharmachem Limited submitted its Annual Secretarial Compliance Report for 2026. This filing supports the company's application to migrate from the NSE SME Emerge platform to the Main Board.
Infinium Pharmachem Limited announced that the resolution for migrating its equity shares from the NSE Emerge platform to the mainboard was passed via postal ballot.
ICRA assigned a new [ICRA]BBB (Stable) rating to Infinium Pharmachem's ₹52.20 Crore credit facilities. The assignment covers cash credit, term loans, and unallocated limits from ICICI Bank and SBI.
Infinium Pharmachem Limited held its 22nd Annual General Meeting on September 17, 2026. Shareholders transacted ordinary and special business, including director appointments and remuneration revisions.